|
- Preclinical and clinical studies of a tumor targeting IL-12 . . .
Here, we review the current knowledge on the use of IL-12 as a cancer therapy, with a particular focus on the mechanism (s) of action and preclinical and clinical development of tumor-targeted NHS-IL12 (recently designated PDS0301, formerly known as M9241)
- Preclinical and clinical studies of a tumor targeting IL-12 immunocytokine
Preclinical studies have examined the rationale for NHS-IL12 combination with tumor necrosis-inducing experimental and standard of care (SOC) therapies aimed at increasing IL-12 targeting to the TME
- Preclinical and clinical studies of a tumor targeting IL-12 immunocytokine
Here we review the preclinical and clinical studies involving NHS-IL12 for the treatment of solid malignancies
- Preclinical and clinical studies of a tumor targeting IL-12 . . .
NHS-IL12 is currently being evaluated clinically in combination with various therapeutic modalities, including chemotherapy, radiation therapy, immune checkpoint inhibition, vaccines, and epigenetic modulation Here we review the preclinical and clinical studies involving NHS-IL12 for the treatment of solid malignancies
- Preclinical and clinical studies of a tumor targeting IL-12 . . .
Here we review the preclinical and clinical studies involving NHS-IL12 for the treatment of solid malignancies Intratumoral administration of mRNA encoding IL-12-based immunocytokines targeting CSF1R and PD-L1 exert potent antitumor effects while restraining systemic exposure to IL-12
- 47 A tumor-targeting IL-12 immunocytokine therapy in patients with . . .
Conclusions PDS01ADC treatment increases peripheral NK cells with specific phenotypes that are positively associated with tumor cell lysis, with increases in some of these phenotypes associating with clinical response
- Novel strategies exploiting interleukin-12 in cancer immunotherapy
In a preclinical study aiming to evaluate the combination of IL-12 with CAR-T cells in solid tumors, IL-12 was shown to attenuate immunosuppressive mechanisms, enhancing efficacy
- Interleukin-12 in multimodal tumor therapies for induction of anti . . .
In this review, we discuss the role of IL-12 as an immunomodulator in promoting anti-tumor effect briefly and the application of IL-12 in combination with other therapies in the preclinical and clinical studies
|
|
|